Aldeyra is committed to developing safe and effective drugs for patients with serious medical conditions.
Dry Eye Disease
Dry eye disease is a common inflammatory disease estimated to affect approximately 20 million people in the United States, and is characterized by insufficient moisture and lubrication in the anterior surface of the eye, leading to dryness, inflammation, pain, discomfort, irritation, and in severe cases, decreased vision.
Allergic conjunctivitis is a common allergic disease that is thought to be mediated in part by pro-inflammatory aldehydes, and is characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, lid swelling and redness.
Noninfectious Anterior Uveitis
Noninfectious anterior uveitis is a rare, potentially blinding disease that may be mediated in part by pro-inflammatory aldehydes, and is characterized by inflammation in the front of the eye, pain, impaired vision, and photophobia.
A topical dermatological therapy is currently being developed by Aldeyra which is intended to facilitate removal of excess fatty aldehydes as a potential treatment for the itchy, dry, scaly skin disease (ichthyosis) in patients with SLS. Future clinical trials of reproxalap may involve systemic administration as a potential treatment for the neurological aspects of the disease.